公开(公告)号：US08388960B2

公开(公告)日：2013-03-05

申请号：US13229422

申请日：2011-09-09

申请人： Viktor S. Goldmakher ,  Robert J. Lutz ,  Ravi V. J. Chari ,  Yelena V. Kovtun ,  John M. Lambert ,  Rita Steeves ,  Hans K. Erickson ,  Wayne C. Widdison

发明人： Viktor S. Goldmakher ,  Robert J. Lutz ,  Ravi V. J. Chari ,  Yelena V. Kovtun ,  John M. Lambert ,  Rita Steeves ,  Hans K. Erickson ,  Wayne C. Widdison

IPC分类号： A61K39/00

CPC分类号： C07K16/3046 ,  A61K31/5383 ,  A61K31/58 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07D498/18 ,  C07K2317/24

摘要： Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.

摘要翻译： 描述了杀死或抑制包含异源或混合细胞群的肿瘤的方法。 通过选择性地靶向疑似在特定细胞群体上表达的独特配体也杀死缺乏独特配体的细胞群体来实现肿瘤的杀伤或抑制。 这些缀合物具有治疗用途，因为它们被递送到特定细胞群以杀死这些细胞，并释放细胞毒性药物以杀死非靶向细胞，从而消除肿瘤。

公开(公告)号：US08137669B2

公开(公告)日：2012-03-20

申请号：US12186411

申请日：2008-08-05

申请人： Viktor S. Goldmakher ,  Robert J. Lutz ,  Ravi V. J. Chari ,  Yelena V. Kovtun ,  John M. Lambert ,  Rita Steeves ,  Hans K. Erickson

发明人： Viktor S. Goldmakher ,  Robert J. Lutz ,  Ravi V. J. Chari ,  Yelena V. Kovtun ,  John M. Lambert ,  Rita Steeves ,  Hans K. Erickson

IPC分类号： A61K39/00

CPC分类号： C07K16/3046 ,  A61K31/5383 ,  A61K31/58 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07D498/18 ,  C07K2317/24

摘要： Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.

摘要翻译： 描述了杀死或抑制包含异源或混合细胞群的肿瘤的方法。 通过选择性地靶向疑似在特定细胞群体上表达的独特配体也杀死缺乏独特配体的细胞群体来实现肿瘤的杀伤或抑制。 这些缀合物具有治疗用途，因为它们被递送到特定细胞群以杀死这些细胞，并释放细胞毒性药物以杀死非靶向细胞，从而消除肿瘤。

公开(公告)号：US20090076263A1

公开(公告)日：2009-03-19

申请号：US12186411

申请日：2008-08-05

申请人： Viktor S. Goldmakher ,  Robert J. Lutz ,  Ravi V.J. Chari ,  Yelena V. Kovtun ,  John M. Lambert ,  Rita Steeves ,  Hans K. Erickson

发明人： Viktor S. Goldmakher ,  Robert J. Lutz ,  Ravi V.J. Chari ,  Yelena V. Kovtun ,  John M. Lambert ,  Rita Steeves ,  Hans K. Erickson

IPC分类号： C07D498/12

CPC分类号： C07K16/3046 ,  A61K31/5383 ,  A61K31/58 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07D498/18 ,  C07K2317/24

摘要： Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.

摘要翻译： 描述了杀死或抑制包含异源或混合细胞群的肿瘤的方法。 通过选择性地靶向疑似在特定细胞群体上表达的独特配体也杀死缺乏独特配体的细胞群体来实现肿瘤的杀伤或抑制。 这些缀合物具有治疗用途，因为它们被递送到特定细胞群以杀死这些细胞，并释放细胞毒性药物以杀死非靶向细胞，从而消除肿瘤。

公开(公告)号：US20060233814A1

公开(公告)日：2006-10-19

申请号：US11404001

申请日：2006-04-14

申请人： Viktor Goldmakher ,  Robert Lutz ,  Ravi Chari ,  Yelena Kovtun ,  John Lambert ,  Rita Steeves ,  Hans Erickson

发明人： Viktor Goldmakher ,  Robert Lutz ,  Ravi Chari ,  Yelena Kovtun ,  John Lambert ,  Rita Steeves ,  Hans Erickson

IPC分类号： A61K39/395 ,  A61K31/5383 ,  C07K16/46 ,  A61K31/58 ,  A61K38/19

CPC分类号： C07K16/3046 ,  A61K31/5383 ,  A61K31/58 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07D498/18 ,  C07K2317/24

摘要： Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.

公开(公告)号：US20050169933A1

公开(公告)日：2005-08-04

申请号：US10960602

申请日：2004-10-08

申请人： Rita Steeves ,  Robert Lutz ,  Ravi Chari ,  Hongsheng Xie ,  Yelena Kovtun

发明人： Rita Steeves ,  Robert Lutz ,  Ravi Chari ,  Hongsheng Xie ,  Yelena Kovtun

IPC分类号： A61K39/395 ,  C07K16/46 ,  C07D491/04

CPC分类号： C07K16/3092 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6889 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/92

摘要： The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.

摘要翻译： 本发明公开了一种将美登木素生物素靶向选定的细胞群体的方法，所述方法包括将怀疑含有所选细胞群的细胞群体或组织与细胞粘附剂美登木素生物碱缀合物接触，其中一种或多种美登木素生物碱共价连接到 细胞结合剂通过不可切割的接头和细胞结合剂结合所选细胞群的细胞。

公开(公告)号：US20080171865A1

公开(公告)日：2008-07-17

申请号：US11927235

申请日：2007-10-29

申请人： Rita Steeves ,  Robert Lutz ,  Ravi Chari ,  Hongsheng Xie ,  Yelena Kovtun

发明人： Rita Steeves ,  Robert Lutz ,  Ravi Chari ,  Hongsheng Xie ,  Yelena Kovtun

IPC分类号： C07D498/08

CPC分类号： C07K16/3092 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6889 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/92

摘要： The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.

摘要翻译： 本发明公开了一种将美登木素生物素靶向选定的细胞群体的方法，所述方法包括将怀疑含有所选细胞群的细胞群体或组织与细胞粘附剂美登木素生物碱缀合物接触，其中一种或多种美登木素生物碱共价连接到 细胞结合剂通过不可切割的接头和细胞结合剂结合所选细胞群的细胞。

公开(公告)号：US20080114153A1

公开(公告)日：2008-05-15

申请号：US11927217

申请日：2007-10-29

申请人： Rita Steeves ,  Robert Lutz ,  Ravi Chari ,  Hongsheng Xie ,  Yelena Kovtun

发明人： Rita Steeves ,  Robert Lutz ,  Ravi Chari ,  Hongsheng Xie ,  Yelena Kovtun

IPC分类号： C07K14/705 ,  C07D491/14

CPC分类号： C07K16/3092 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6889 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/92

摘要： The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.

公开(公告)号：US20060127407A1

公开(公告)日：2006-06-15

申请号：US11290249

申请日：2005-11-30

申请人： Qiming Chen ,  Mohit Trikha ,  Robert Lutz ,  Rita Steeves ,  Godfrey Amphlett

发明人： Qiming Chen ,  Mohit Trikha ,  Robert Lutz ,  Rita Steeves ,  Godfrey Amphlett

IPC分类号： A61K39/395 ,  C07K16/46

CPC分类号： A61K47/48569 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2839 ,  C07K2317/21 ,  C07K2317/73

摘要： The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.